Author Archives: developer

NiKang Therapeutics Enters Into Clinical Trial Collaboration and Supply Agreement to Evaluate NKT2152 in Combination with Standard-of-Care in First-Line Advanced Hepatocellular Carcinoma

See the press release on Business Wire

NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors

See the press release on Business Wire

NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China

See the press release on Business Wire

NiKang Therapeutics Presents Preclinical Data Highlighting NKT2152’s Therapeutic Potential in Clear Cell Renal Cell Carcinoma (ccRCC) and Solid Tumors Beyond ccRCC at AACR Annual Meeting 2022

See the press release on Business Wire

NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma

See the press release on Business Wire

NiKang Therapeutics Announces First Patient Dosed in A Phase 1/2 Study Evaluating NKT2152, a Small Molecule that Inhibits Hypoxia Inducible Factor 2α (HIF2α), for the Treatment of Advanced Clear Cell Renal Cell Carcinoma

See the press release on Business Wire

NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets

See the press release on Business Wire

NiKang Therapeutics Appoints Kelsey Chen, Ph.D., MBA, as Chief Financial Officer

See the press release on EIN Newswire

Erasca announced the dosing of a first patient in December 2020 in Erasca’s FLAGSHP-1 study, a Phase 1/1b clinical trial to evaluate ERAS-601, a SHP2 inhibitor discovered and developed by NiKang Therapeutics

See the press release on Business Wire

NiKang Therapeutics Completes $50 Million Series B Financing

See the press release on EIN Newswire